Published in J Clin Invest on December 01, 1984
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med (2002) 7.99
Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol (2007) 2.67
The eicosanoids and their biochemical mechanisms of action. Biochem J (1989) 2.35
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol (2004) 1.62
Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol (2009) 1.42
Dietary fish oil modulates macrophage fatty acids and decreases arthritis susceptibility in mice. J Exp Med (1985) 1.41
Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest (1985) 1.36
TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. J Physiol (2006) 1.25
Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLoS One (2013) 1.10
The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids (2009) 1.08
Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol (2009) 1.07
Effect of dietary supplementation with fish oil lipids on mild asthma. Thorax (1988) 1.06
Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLoS One (2012) 1.01
Consequences of essential fatty acids. Nutrients (2012) 0.99
Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr (2010) 0.87
Impact of botanical oils on polyunsaturated fatty acid metabolism and leukotriene generation in mild asthmatics. Lipids Health Dis (2013) 0.86
In vivo chemotaxis of bovine neutrophils induced by 5-lipoxygenase metabolites of arachidonic and eicosapentaenoic acid. Am J Pathol (1989) 0.86
DHA metabolism: targeting the brain and lipoxygenation. Mol Neurobiol (2010) 0.86
Acyl-chain selectivity of the 85 kDa phospholipase A2 and of the release process in intact macrophages. Biochem J (1994) 0.84
Dietary fish oil blocks the microcirculatory manifestations of ischemia-reperfusion injury in striated muscle in hamsters. Proc Natl Acad Sci U S A (1991) 0.84
Intravenous infusion of tridocosahexaenoyl-glycerol emulsion into rabbits. Effects on leukotriene B4/5 production and fatty acid composition of plasma and leukocytes. J Clin Invest (1993) 0.83
Hepatic transcriptome analysis of inter-family variability in flesh n-3 long-chain polyunsaturated fatty acid content in Atlantic salmon. BMC Genomics (2012) 0.83
Stimulus-specific induction of phospholipid and arachidonic acid metabolism in human neutrophils. J Cell Biol (1987) 0.82
Biosynthesis of platelet-activating factor (PAF) in human polymorphonuclear leucocytes. The role of lyso-PAF disposal and free arachidonic acid. Biochem J (1990) 0.82
Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis. Clin Exp Immunol (1994) 0.81
Dietary fish oil substitution alters the eicosanoid profile in ankle joints of mice during Lyme infection. J Nutr (2012) 0.80
Adipose tissue arachidonic acid content is associated with the expression of 5-lipoxygenase in atherosclerotic plaques. Lipids Health Dis (2013) 0.79
The role of arachidonic acid metabolites in local and systemic inflammatory processes. Drugs (1987) 0.79
Metabolic interactions between eicosanoids in blood and vascular cells. Biochem J (1989) 0.79
Anti-inflammatory effects of eicosapentaenoic acid on experimental skin inflammation models. Arch Dermatol Res (1993) 0.78
Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund's Adjuvant-induced knee arthritis. Arthritis Res Ther (2014) 0.78
Defects in prostaglandin synthesis and metabolism in ulcer disease. Dig Dis Sci (1986) 0.77
Oxidized eicosapentaenoic acids more potently reduce LXRα-induced cellular triacylglycerol via suppression of SREBP-1c, PGC-1β and GPA than its intact form. Lipids Health Dis (2013) 0.76
Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. Ann Surg (1988) 0.76
Effect of fish oil on neutrophil chemiluminescence induced by different stimuli in patients with rheumatoid arthritis. Ann Rheum Dis (1992) 0.76
Asymmetric Binding and Metabolism of Polyunsaturated Fatty Acids (PUFAs) by CYP2J2 Epoxygenase. Biochemistry (2016) 0.76
LEUKOCYTE LIPID BODIES - STRUCTURE AND FUNCTION AS "EICOSASOMES". Trans Am Clin Climatol Assoc (2016) 0.75
Nrf2 Activation by 5-lipoxygenase Metabolites in Human Umbilical Vascular Endothelial Cells. Nutrients (2017) 0.75
Vitamin D prenatal programming of childhood metabolomics profiles at age 3 y. Am J Clin Nutr (2017) 0.75
Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl (1968) 60.35
A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods (1980) 6.44
Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc Natl Acad Sci U S A (1979) 6.34
Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A (1979) 5.33
Prostaglandins and thromboxanes. Annu Rev Biochem (1978) 3.47
Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem (1979) 3.16
Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci U S A (1979) 3.14
Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J Biol Chem (1979) 3.08
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A (1979) 2.07
Identification and biological activity of novel omega-oxidized metabolites of leukotriene B4 from human leukocytes. FEBS Lett (1981) 2.04
Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A (1983) 1.91
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
Metabolism of arachidonic acid in ionophore-stimulated neutrophils. Esterification of a hydroxylated metabolite into phospholipids. J Clin Invest (1979) 1.77
cis-Polyunsaturated fatty acids induce high levels of superoxide production by human neutrophils. J Biol Chem (1981) 1.75
Human alveolar macrophages produce leukotriene B4. Proc Natl Acad Sci U S A (1982) 1.67
Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A (1983) 1.67
Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem (1984) 1.56
Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun (1983) 1.51
Radioimmunoassay of the leukotrienes of slow reacting substance of anaphylaxis. Proc Natl Acad Sci U S A (1981) 1.45
Leukotriene B4 production by the human alveolar macrophage: a potential mechanism for amplifying inflammation in the lung. Am Rev Respir Dis (1984) 1.45
Formation of novel hydroxylated eicosatetraenoic acids in preparations of human polymorphonuclear leukocytes. FEBS Lett (1981) 1.44
Release of chemical mediators from partially purified human lung mast cells. J Immunol (1976) 1.44
Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol (1984) 1.39
Arachidonate 5-lipoxygenase of guinea pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5'-triphosphate. J Biol Chem (1983) 1.39
Leukotriene A. Isolation from human polymorphonuclear leukocytes. J Biol Chem (1980) 1.28
Biosynthesis and biological activity of leukotriene B5. Prostaglandins (1984) 1.27
Contractile activities of several cysteine-containing leukotrienes in the guinea-pig lung strip. Eur J Pharmacol (1982) 1.11
Uptake, release and metabolism of docosahexaenoic acid (DHA, c22:6 omega 3) in human platelets and neutrophils. Biochem Biophys Res Commun (1984) 1.11
Radioimmunoassay for leukotriene B4. Proc Natl Acad Sci U S A (1982) 1.05
Nutritional properties of fish oils. World Rev Nutr Diet (1969) 1.03
Synthesis of hydroxy fatty acids from 4, 7, 10, 13, 16, 19-[1-14C] docosahexaenoic acid by human platelets. J Biol Chem (1983) 1.01
Leukotriene C5: a slow reacting substance derived from eicosapentaenoic acid. J Biol Chem (1980) 0.94
Effect of docosahexaenoic acid (DHA) on arachidonic acid metabolism and platelet function. Biochem Biophys Res Commun (1983) 0.92
Immunologically induced generation of tetraene and pentaene leukotrienes in the peritoneal cavities of menhaden-fed rats. J Immunol (1984) 0.91
Detection of leukotriene A4 as an intermediate in the biosynthesis of leukotrienes C4 and D4. FEBS Lett (1980) 0.86
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet (1997) 10.93
Does housestaff discontinuity of care increase the risk for preventable adverse events? Ann Intern Med (1994) 10.29
CARBOHYDRATE METABOLISM IN ADDISON'S DISEASE. J Clin Invest (1940) 9.89
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
A pigment-binding protein essential for regulation of photosynthetic light harvesting. Nature (2000) 6.97
Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell (1982) 6.93
Cyclin activation of p34cdc2. Cell (1990) 6.87
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Contaminant blood cultures and resource utilization. The true consequences of false-positive results. JAMA (1991) 6.28
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 6.00
RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell (1995) 5.73
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A (1979) 5.32
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science (2001) 5.22
Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A (1999) 5.08
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 4.72
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
Physician reporting compared with medical-record review to identify adverse medical events. Ann Intern Med (1993) 4.60
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
THE EFFECT OF 17-HYDROXYCORTICOSTERONE AND RELATED ADRENAL CORTICAL STEROIDS ON SODIUM AND CHLORIDE EXCRETION. Science (1941) 3.45
Keratin cytoskeletons in epithelial cells of internal organs. Proc Natl Acad Sci U S A (1979) 3.45
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Triggering myocardial infarction by marijuana. Circulation (2001) 3.36
Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest (1994) 3.31
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Predicting bacteremia in hospitalized patients. A prospectively validated model. Ann Intern Med (1990) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat (2001) 3.07
Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem (1991) 3.06
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med (1995) 3.03
Rapid classification of positive blood cultures. Prospective validation of a multivariate algorithm. JAMA (1992) 3.02
Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med (1993) 3.00
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Molecular genetics of human blue cone monochromacy. Science (1989) 2.92
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Heterogeneity of therapeutic responses in asthma. Br Med Bull (2000) 2.86
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Three different human tumor cell lines contain different oncogenes. Cell (1981) 2.77
Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat (2003) 2.75
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet (1994) 2.72
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol (1990) 2.60